Sebastian Andersen, CEO and founder of ClarityNorth Partners, discusses H1 2026 biopharma M&A, oncology deal activity, Lilly’s strategy, capital deployment, and how transaction structure can help companies manage risk.
Sebastian Andersen
Advertisement
Sebastian Andersen is CEO and founder of ClarityNorth Partners.
Articles by Sebastian Andersen
Sebastian Andersen, CEO and founder of ClarityNorth Partners, discusses 2026 biopharma dealmaking, including M&A trends, oncology deal activity, Lilly’s acquisition strategy, and how transaction structure can help companies manage risk.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Policy Leaders Urge Treasury to Narrow Biotech Outbound Investment Rule
2
Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India
3
Spyre’s Anti-TL1A Antibody SPY072 Misses in Psoriatic Arthritis and Axial Spondyloarthritis, Shifts Focus to Hidradenitis Suppurativa
4
Boehringer Ingelheim Licenses Six Preclinical ADC and T-Cell Engager Programs From SBP Group in Deal Worth Up to $7 Billion
5